Potential Drug Candidates Underway Several Registered Clinical Trials
for Battling COVID-19
Abstract
The emergence of new type of viral pneumonia cases in China, on December
31, 2019; identified as the cause of human coronavirus, labeled as
“COVID-19,” took a heavy toll of death and reported cases of infected
people all over the world, with the potential to spread widely and
rapidly, achieved worldwide prominence but arose without the procurement
guidance. There is an immediate need for active intervention and fast
drug discovery against the 2019-nCoV outbreak. Herein, the study
provides numerous candidates of drugs (either alone or integrated with
another drugs) which could prove to be effective against 2019-nCoV, are
under different stages of clinical trials. This review will offer rapid
identification of a number of repurposable drugs and potential drug
combinations targeting 2019-nCoV and preferentially allow the
international research community to evaluate the findings, to validate
the efficacy of the proposed drugs in prospective trials and to lead
potential clinical practices.